FIELD: chemistry.
SUBSTANCE: invention relates to the crystal forms of methanesulfonate (A, B and C forms), methanesulfonate hydrate (F form), solvate with the acetic acid of methanesulfonate (I form), ethanesulfonate (α and β forms), hydrochloride, hydrobromide, n-toluenesulfonate or sulfate 4-(3-chlorine-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, to the methods of their production, to the pharmaceutical compositions based on them and showing the angiogenesis related activity, to the method of prevention or treatment of the disease where inhibiting angiogenesis is effective and to the application of the crystal forms in producing the pharmaceutical agent for prevention or treatment of the disease where inhibiting angiogenesis is effective.
EFFECT: producing the pharmaceutical agent for prevention or treatment of the disease where inhibiting angiogenesis is effective.
45 cl, 21 dwg, 27 tbl, 13 ex
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMPOSITION CONTAINING QUINOLINE DERIVATIVE | 2010 |
|
RU2548673C2 |
HIGH-PURITY QUINOLINE DERIVATIVE AND ITS PRODUCTION METHOD | 2015 |
|
RU2785875C2 |
ANTICANCER DRUG FOR THYROID CANCER | 2007 |
|
RU2448708C2 |
ANTICANCER THERAPEUTIC AGENT | 2012 |
|
RU2580609C2 |
CRYSTALS OF DIPYROPYRROLIDINE DERIVATIVES | 2013 |
|
RU2647840C2 |
ACID ADDITION SALT OF TRK INHIBITING COMPOUND | 2015 |
|
RU2708236C2 |
CRYSTALLINE MODIFICATIONS OF 3-(1H-INDOL-3-YL)-4-(4-METHYLPIPERAZIN-1-YL)QUINAZOLIN-4-YL)PYRROL-2,5-DIONE | 2007 |
|
RU2481341C2 |
5-HYDROXY-1H-IMIDAZOLE-4-CARBOXAMIDE SULPHATE | 2014 |
|
RU2603137C1 |
SALT OF MONOCYCLIC DERIVATIVE OF PYRIDINE AND CRYSTAL THEREOF | 2015 |
|
RU2658821C1 |
NONHYGROSCOPIC CRYSTALLINE 5-[(Z)-(5-FLUORO-2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]-N-[(2S)-2-HYDROXY-3-MORPHOLIN-4-YLPROPYL]-2,4-DIMETHYL-1H-PYRROL-3-CARBOXAMIDE MALEATE SALT, PHARMACEUTICAL COMPOSITION AND METHOD FOR CANCER TREATMENT | 2004 |
|
RU2319702C2 |
Authors
Dates
2008-07-10—Published
2004-12-22—Filed